To the full analysis
Buyback calculator for Hansa Biopharma
Hansa Biopharma stock: key metrics
HNSA.STHansa Biopharma had an operating margin of −234.3% and a return on invested capital (ROIC) of −57.2% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2008 | 100.0% | −15,341.7% | −2,467.5% |
| 2009 | 100.0% | −527.5% | −529.9% |
| 2010 | 100.0% | −449.5% | −423.6% |
| 2011 | −33.7% | 1,908.0% | −1,916.4% |
| 2012 | 195.0% | −641.8% | −628.8% |
| 2013 | 81.6% | −1,021.4% | −1,016.9% |
| 2014 | 94.8% | −523.9% | −615.8% |
| 2015 | 87.9% | −1,218.3% | −1,219.5% |
| 2016 | 91.6% | −4,309.2% | −4,309.0% |
| 2017 | 93.6% | −5,115.7% | −5,132.5% |
| 2018 | 72.7% | −7,340.6% | −7,384.6% |
| 2019 | 74.3% | −10,630.1% | −10,701.8% |
| 2020 | 83.7% | −6,970.8% | −6,901.5% |
| 2021 | 54.5% | −1,592.7% | −1,618.4% |
| 2022 | 75.1% | −372.8% | −395.5% |
| 2023 | 52.9% | −588.0% | −620.3% |
| 2024 | 51.2% | −372.3% | −471.2% |
| 2025 | 62.4% | −234.3% | −240.3% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2008 | −6.3% | −22.8% | −5.7% |
| 2009 | −63.4% | −37.0% | −41.5% |
| 2010 | −58.6% | −49.2% | −49.8% |
| 2011 | −70.8% | 59.0% | −60.1% |
| 2012 | −26.0% | −34.1% | −25.0% |
| 2013 | −38.4% | −30.8% | −34.6% |
| 2014 | −58.3% | −45.5% | −53.5% |
| 2015 | −31.3% | −40.0% | −29.6% |
| 2016 | −39.2% | −35.4% | −35.8% |
| 2017 | −28.0% | −30.2% | −26.0% |
| 2018 | −28.8% | −26.4% | −26.2% |
| 2019 | −64.0% | −40.1% | −54.2% |
| 2020 | −33.9% | −35.9% | −29.3% |
| 2021 | −72.4% | −39.8% | −54.1% |
| 2022 | −100.0% | −40.2% | −36.2% |
| 2023 | 200.0% | −58.6% | −81.7% |
| 2024 | 136.9% | −80.7% | −100.0% |
| 2025 | 200.0% | −57.2% | −45.8% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = SEK 9.9729)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jan 2015)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.